Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

SHAREHOLDER ALERT: DBD OMCL NFLX KPTI: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines

NFLX, OMCL, KPTI

NEW YORK, Aug. 06, 2019 (GLOBE NEWSWIRE) -- The Law Offices of Vincent Wong announce that class actions have commenced on behalf of shareholders of the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff.

Diebold Nixdorf, Incorporated (NYSE: DBD)
Lead Plaintiff Deadline: September 3, 2019
Class Period: February 14, 2017 and July 4, 2017

Get additional information about DBD: http://www.wongesq.com/pslra-1/diebold-nixdorf-incorporated-loss-submission-form?wire=3 

Omnicell, Inc. (NASDAQGS: OMCL)
Lead Plaintiff Deadline: September 16, 2019
Class Period: October 25, 2018 and July 11, 2019

Get additional information about OMCL: http://www.wongesq.com/pslra-1/omnicell-inc-loss-submission-form?wire=3 

Netflix, Inc. (NASDAQGS: NFLX)
Lead Plaintiff Deadline: September 20, 2019
Class Period: April 17, 2019 and July 17, 2019

Get additional information about NFLX: http://www.wongesq.com/pslra-1/netflix-inc-loss-submission-form?wire=3 

Karyopharm Therapeutics Inc (NASDAQGS: KPTI)
Lead Plaintiff Deadline: September 23, 2019
Class Period: on behalf of shareholders of Karyopharm Therapeutics Inc. who: (1) purchased shares of Karyopharm’s common stock between March 2, 2017 and February 22, 2019, inclusive; (2) purchased Karyopharm shares in or traceable to the Company’s public offering of common stock conducted on or around April 28, 2017; or (3) purchased Karyopharm shares in or traceable to the Company’s public offering of common stock conducted on or around May 7, 2018.

Get additional information about KPTI: http://www.wongesq.com/pslra-1/karyopharm-therapeutics-inc-loss-submission-form?wire=3 

To learn more contact Vincent Wong, Esq. either via email vw@wongesq.com or by telephone at 212.425.1140.

Vincent Wong, Esq. is an experienced attorney that has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
Vincent Wong, Esq.
39 East Broadway
Suite 304
New York, NY 10002
Tel. 212.425.1140
Fax. 866.699.3880
E-Mail: vw@wongesq.com

Primary Logo